Oncorus (ONCR) Stock Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. More details

ONCR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Earnings have declined by 25.8% per year over past 5 years

Does not have a meaningful market cap ($3M)

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

+ 1 more risk

ONCR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,641 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

440,641 investors already sharing narratives

View all narratives

Oncorus, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oncorus
Historical stock prices
Current Share Price	US$0.13
52 Week High	US$0.47
52 Week Low	US$0.01
Beta	1.95
1 Month Change	500.00%
3 Month Change	427.20%
1 Year Change	-58.00%
3 Year Change	-99.63%
5 Year Change	n/a
Change since IPO	-99.21%

Recent updates

Seeking Alpha • Aug 04

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus press release (NASDAQ:ONCR): Q2 GAAP EPS of -$0.74 misses by $0.02. Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022 Company remains on track to submit IND for ONCR-021 in mid-2023 Ended quarter with $100.2 million in cash and cash equivalents to support next-generation viral immunotherapy pipeline

Analysis Article • Oct 14

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Jul 09

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus shares have been in steady decline since nearly doubling in value less than six months after the company's October 2020 IPO. Current trading price of $13 is slightly under the $15 IPO price, but the biotech has just entered the clinic with its first viral oncolytic therapy, ONCR-177. The therapy uses the herpes simplex virus to gain entry to tumor cells, where it unleashes five different immunomodulatory payloads. The heavily engineered therapy has numerous questions to answer in the clinic. In preclinical mouse models, the safety and potency profile of ONCR-177 looked strong. Markets including melanoma, breast and colorectal cancer are in play for Oncorus, and longer term, a synthetics platform will target NSCLC and SCLC. Given its opportunity and technology, a market cap

Analysis Article • May 05

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analysis Article • Feb 26

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

A look at the shareholders of Oncorus, Inc. ( NASDAQ:ONCR ) can tell us which group is most powerful. Generally...

Analysis Article • Jan 04

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

	ONCR	US Biotechs	US Market
7D	26.0%	-5.2%	-0.9%
1Y	-58.0%	37.6%	14.2%

Return vs Industry: ONCR underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ONCR underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is ONCR's price volatile compared to industry and market?
ONCR volatility
ONCR Average Weekly Movement	210.0%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

Stable Share Price: ONCR's share price has been volatile over the past 3 months.

Volatility Over Time: ONCR's weekly volatility has increased from 101% to 210% over the past year.

About the Company

Founded	Employees	CEO	Website
2015	64	Craig Jalbert	www.oncorus.com

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Oncorus, Inc. Fundamentals Summary

How do Oncorus's earnings and revenue compare to its market cap?
ONCR fundamental statistics
Market cap	US$3.29m
Earnings (TTM)	-US$90.54m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ONCR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$90.54m
Earnings	-US$90.54m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.47
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	66.0%

How did ONCR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/01/03 07:52
End of Day Share Price	2023/12/29 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncorus, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthew Barcus	Chardan Capital Markets, LLC
Joshua Schimmer	Evercore ISI
Swayampakula Ramakanth	H.C. Wainwright & Co.

Oncorus (ONCR) Stock Overview

Risk Analysis

Join community and earn perks

Oncorus, Inc. Competitors

TC Biopharm (Holdings)

Canton Strategic Holdings

Matinas BioPharma Holdings

Dogwood Therapeutics

Price History & Performance

Recent News & Updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Recent updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Oncorus, Inc. Appoints Alexander Nolte as Principal Accounting Officer

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting

Price target decreased to US$5.75

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Now 23% undervalued

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus, Inc. Appoints Douglas Fambrough to Board of Directors

Oncorus, Inc., Annual General Meeting, Jun 22, 2022

Oncorus, Inc. Announces the Appointment of Richard Wanstall as Chief Financial Officer

Price target decreased to US$17.00

Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Oncorus, Inc. announced that it expects to receive $45 million in funding from K2 HealthVentures

Oncorus, Inc. Promotes John Goldberg to Chief Medical Officer

President exercised options to buy US$184k worth of stock.

COO & Chief of Staff recently bought US$174k worth of stock

Price target decreased to US$34.75

President exercised options to buy US$469k worth of stock.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus, Inc.(NasdaqGM:ONCR) dropped from Russell 3000E Growth Index

Independent Director Robert Kirkman has left the company

Independent Director Cameron Wheeler has left the company

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Insider exercised options to buy US$590k worth of stock.

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

Independent Director has left the company

Oncorus Anticipates Reporting Interim Data from its Ongoing Phase 1 Clinical Trial of its Lead oHSV-Based Clinical Candidate ONCR-177 in Patients with Solid Tumor Indications in the Second Half of 2021

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

New 90-day low: US$20.97

Oncorus, Inc. Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

New 90-day high: US$35.55

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus Appoints Scott Canute to Its Board of Directors

Oncorus, Inc. has filed an IPO in the amount of $86.25 million.

Shareholder Returns

Price Volatility

About the Company

Oncorus, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources